Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 11/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634698 | 0.90 | MAP3K7 (0.47) | MAP3K7FGFR1IRAK4GSK3BDYRK1A | |
| SCHEMBL13634621 | 0.90 | GPR6 (0.39) | FGFR1HRH3GPR6SCD | |
| SCHEMBL13634648 | 0.89 | MAP3K7 (0.51) | MAP3K7FGFR1IRAK4GPR6 | |
| SCHEMBL13634863 | 0.89 | MAP3K7 (0.48) | MAP3K7FGFR1IRAK4GSK3BDYRK1A | |
| SCHEMBL13634702 | 0.89 | HRH3 (0.41) | IRAK4HRH3GPR6SCD | |
| SCHEMBL13634620 | 0.87 | SCD (0.46) | MAP3K7FGFR1IRAK4GSK3BDYRK1A | |
| SCHEMBL13638941 | 0.86 | MAP3K7 (0.43) | MAP3K7FGFR1IRAK4GPR6SCD | |
| SCHEMBL13634882 | 0.81 | MAP3K7 (0.39) | MAP3K7GPR6SCD | |
| SCHEMBL13634619 | 0.79 | SCN9A (0.43) | IRAK4GPR6SCD | |
| SCHEMBL13634880 | 0.79 | RAB9A (0.40) | MAP3K7SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |